Zeitschriftenartikel zum Thema „Fu ci“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Fu ci" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Methot, N., und K. Basler. „Suppressor of fused opposes hedgehog signal transduction by impeding nuclear accumulation of the activator form of Cubitus interruptus“. Development 127, Nr. 18 (15.09.2000): 4001–10. http://dx.doi.org/10.1242/dev.127.18.4001.
Der volle Inhalt der QuelleZhou, Mengmeng, Yuhong Han, Bing Wang, Yong Suk Cho und Jin Jiang. „Dose-dependent phosphorylation and activation of Hh pathway transcription factors“. Life Science Alliance 5, Nr. 11 (05.09.2022): e202201570. http://dx.doi.org/10.26508/lsa.202201570.
Der volle Inhalt der QuelleKöhne, C.-H., J. Wils, M. Lorenz, P. Schöffski, R. Voigtmann, C. Bokemeyer, M. Lutz et al. „Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952“. Journal of Clinical Oncology 21, Nr. 20 (15.10.2003): 3721–28. http://dx.doi.org/10.1200/jco.2003.11.122.
Der volle Inhalt der QuelleKabbinavar, Fairooz, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing und Emily Bergsland. „Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer“. Journal of Clinical Oncology 21, Nr. 1 (01.01.2003): 60–65. http://dx.doi.org/10.1200/jco.2003.10.066.
Der volle Inhalt der QuelleKu, Geoffrey Yuyat, Benjamin Haaland und Gilberto de Lima Lopes. „Cetuximab (C225) in the first-line treatment of advanced colorectal cancer (CRC) patients (Pts) with K-ras wild-type (WT) tumors: Does the choice and schedule of fluoropyrimidine (Fp) matter?“ Journal of Clinical Oncology 30, Nr. 4_suppl (01.02.2012): 576. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.576.
Der volle Inhalt der QuelleWang-Gillam, Andrea, Chung-Pin Li, Gyorgy Bodoky, Andrew Dean, Yang-Shen Shan, Gayle S. Jameson, Teresa Macarulla et al. „Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.“ Journal of Clinical Oncology 34, Nr. 4_suppl (01.02.2016): 417. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.417.
Der volle Inhalt der QuelleWagner, Anna D., Wilfried Grothe, Johannes Haerting, Gerhard Kleber, Axel Grothey und Wolfgang E. Fleig. „Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data“. Journal of Clinical Oncology 24, Nr. 18 (20.06.2006): 2903–9. http://dx.doi.org/10.1200/jco.2005.05.0245.
Der volle Inhalt der QuelleArkenau, Hendrik-Tobias, Dirk Arnold, Jim Cassidy, Eduardo Diaz-Rubio, Jean-Yves Douillard, Howard Hochster, Andrea Martoni et al. „Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials“. Journal of Clinical Oncology 26, Nr. 36 (20.12.2008): 5910–17. http://dx.doi.org/10.1200/jco.2008.16.7759.
Der volle Inhalt der QuelleNam, Ki-Woong, Chi Kyung Kim, Tae Jung Kim, Kyungmi Oh, Moon-Ku Han, Sang-Bae Ko und Byung-Woo Yoon. „FLAIR vascular hyperintensities predict early ischemic recurrence in TIA“. Neurology 90, Nr. 9 (31.01.2018): e738-e744. http://dx.doi.org/10.1212/wnl.0000000000005034.
Der volle Inhalt der QuellePoplin, Elizabeth A., Jacqueline K. Benedetti, Norman C. Estes, Daniel G. Haller, Robert J. Mayer, Richard M. Goldberg, Geoffrey R. Weiss, Saul E. Rivkin und John S. Macdonald. „Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer“. Journal of Clinical Oncology 23, Nr. 9 (20.03.2005): 1819–25. http://dx.doi.org/10.1200/jco.2005.04.169.
Der volle Inhalt der QuelleSisson, Barbara E., Suzanne L. Ziegenhorn und Robert A. Holmgren. „Regulation of Ci and Su(fu) nuclear import in Drosophila“. Developmental Biology 294, Nr. 1 (Juni 2006): 258–70. http://dx.doi.org/10.1016/j.ydbio.2006.02.050.
Der volle Inhalt der QuelleSchilsky, Richard L., Jeremey Levin, William H. West, Alfred Wong, Bruce Colwell, Michael P. Thirlwell, Rafat H. Ansari et al. „Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer“. Journal of Clinical Oncology 20, Nr. 6 (15.03.2002): 1519–26. http://dx.doi.org/10.1200/jco.2002.20.6.1519.
Der volle Inhalt der QuelleHoning, Judith, Justin Smit, Christina Muijs, Johannes Burgerhof, Jannet Beukema, John Theodorus Plukker und Geke Hospers. „A comparison of carboplatin with paclitaxel and cisplatinum with 5-fluorouracil in definitive chemoradiotherapy in esophageal cancer patients.“ Journal of Clinical Oncology 32, Nr. 3_suppl (20.01.2014): 104. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.104.
Der volle Inhalt der QuelleSultana, Asma, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P. Neoptolemos und Paula Ghaneh. „Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer“. Journal of Clinical Oncology 25, Nr. 18 (20.06.2007): 2607–15. http://dx.doi.org/10.1200/jco.2006.09.2551.
Der volle Inhalt der QuelleRao, Sheela, Francesco Sclafani, Cathy Eng, Richard A. Adams, Marianne G. Guren, David Sebag-Montefiore, Al Benson et al. „International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct“. Journal of Clinical Oncology 38, Nr. 22 (01.08.2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.
Der volle Inhalt der QuelleSchmoll, Hans-Joachim, Josep Tabernero, Jean Alfred Maroun, Filippo G. De Braud, Timothy Jay Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger und Daniel G. Haller. „Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).“ Journal of Clinical Oncology 30, Nr. 4_suppl (01.02.2012): 388. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.388.
Der volle Inhalt der QuelleDouillard, Jean-Yves, Paulo M. Hoff, Jamey R. Skillings, Peter Eisenberg, Neville Davidson, Peter Harper, Mark D. Vincent et al. „Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer“. Journal of Clinical Oncology 20, Nr. 17 (01.09.2002): 3605–16. http://dx.doi.org/10.1200/jco.2002.04.123.
Der volle Inhalt der QuelleYang Seoung Duk. „A Study on the Ci-Fu Thoughts of Xie-Ling-Yun“. Journal of Chinese Language and Literature ll, Nr. 54 (Dezember 2009): 83–104. http://dx.doi.org/10.15792/clsyn..54.200912.83.
Der volle Inhalt der QuelleYang, Seoung Duk. „A Study on The theory of Dong-Jin,s Ci-Fu“. JOURNAL OF CHINESE HUMANITIES 76 (31.12.2020): 223–43. http://dx.doi.org/10.35955/jch.2020.12.76.223.
Der volle Inhalt der QuelleCassidy, J., N. Scotto und E. Diaz-Rubio. „Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer.“ Journal of Clinical Oncology 29, Nr. 4_suppl (01.02.2011): 495. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.495.
Der volle Inhalt der QuelleMerchant, Mark, Felix F. Vajdos, Mark Ultsch, Henry R. Maun, Ulrich Wendt, Jennifer Cannon, William Desmarais, Robert A. Lazarus, Abraham M. de Vos und Frederic J. de Sauvage. „Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism“. Molecular and Cellular Biology 24, Nr. 19 (01.10.2004): 8627–41. http://dx.doi.org/10.1128/mcb.24.19.8627-8641.2004.
Der volle Inhalt der QuelleMaisey, Nick, Ian Chau, David Cunningham, Andrew Norman, Matt Seymour, Tamas Hickish, Tim Iveson et al. „Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer“. Journal of Clinical Oncology 20, Nr. 14 (15.07.2002): 3130–36. http://dx.doi.org/10.1200/jco.2002.09.029.
Der volle Inhalt der QuelleBertagnolli, Monica M., Donna Niedzwiecki, Carolyn C. Compton, Hejin P. Hahn, Margaret Hall, Beatrice Damas, Scott D. Jewell et al. „Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803“. Journal of Clinical Oncology 27, Nr. 11 (10.04.2009): 1814–21. http://dx.doi.org/10.1200/jco.2008.18.2071.
Der volle Inhalt der QuelleWang-Gillam, Andrea, Richard Hubner, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger und Li-Tzong Chen. „Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.“ Journal of Clinical Oncology 36, Nr. 4_suppl (01.02.2018): 388. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.388.
Der volle Inhalt der QuelleTaïeb, Julien, Tim Maughan, Carsten Bokemeyer, Eric Van Cutsem, Thomas Brodowicz, Gunnar Folprecht, Regina Esser, Michael Schlichting und Josep Tabernero. „Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): 3574. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3574.
Der volle Inhalt der QuelleWagner, A. D., W. Grothe, J. Haerting, G. Kleber, A. Grothey und W. E. Fleig. „Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis“. Journal of Clinical Oncology 25, Nr. 18_suppl (20.06.2007): 4555. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4555.
Der volle Inhalt der QuelleSchmoll, Hans-Joachim, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger und Daniel G. Haller. „Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial“. Journal of Clinical Oncology 33, Nr. 32 (10.11.2015): 3733–40. http://dx.doi.org/10.1200/jco.2015.60.9107.
Der volle Inhalt der QuelleSizer, B., A. Makris, C. Barone, P. Mainwaring und P. Eggleton. „QoL and resource use analysis of tegafur-uracil/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 3631. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3631.
Der volle Inhalt der QuelleKöhne, C. H., E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M. P. Lutz, M. Lorenz et al. „Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986“. Journal of Clinical Oncology 23, Nr. 22 (01.08.2005): 4856–65. http://dx.doi.org/10.1200/jco.2005.05.546.
Der volle Inhalt der QuellePeng, Chengwei, Saad Saffo, Michael Shusterman, Daniel Jacob Becker, Jordan Berlin, Paul Eliezer Oberstein, Anil Nagar und Shun Yu. „Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.“ Journal of Clinical Oncology 41, Nr. 4_suppl (01.02.2023): 59. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.59.
Der volle Inhalt der QuelleFuchs, Charles S., Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S. Swanson, Peter C. Enzinger et al. „Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)“. Journal of Clinical Oncology 35, Nr. 32 (10.11.2017): 3671–77. http://dx.doi.org/10.1200/jco.2017.74.2130.
Der volle Inhalt der QuelleLi, Jia-yi, Xuan-zhang Huang, Peng Gao, Xiao-wan Chen, Yong-xi Song, Xing-er Lv, Yv Fu, Qiong Xiao und Zhen-ning Wang. „Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment“. BioMed Research International 2021 (27.03.2021): 1–21. http://dx.doi.org/10.1155/2021/8852699.
Der volle Inhalt der QuelleWang, Aiqing. „Cliché-ridden Online Danmei Fiction? A Case Study of Tianguan ci fu“. Acta Asiatica Varsoviensia 35 (2022): 281–314. http://dx.doi.org/10.60018/acasva.iray5065.
Der volle Inhalt der QuelleSchmidt, Jan, Ulrich Abel, Jürgen Debus, Sabine Harig, Katrin Hoffmann, Thomas Herrmann, Detlef Bartsch et al. „Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma“. Journal of Clinical Oncology 30, Nr. 33 (20.11.2012): 4077–83. http://dx.doi.org/10.1200/jco.2011.38.2960.
Der volle Inhalt der QuelleModest, Dominik Paul, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Alexander Koenig, Ludwig Fischer von Weikersthal et al. „FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): 3506. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3506.
Der volle Inhalt der QuelleYothers, Greg, Patricia A. Ganz, Samia H. Lopa, Clifford Y. Ko, D. Lawrence Wickerham und Norman Wolmark. „Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04.“ Journal of Clinical Oncology 30, Nr. 4_suppl (01.02.2012): 391. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.391.
Der volle Inhalt der QuelleSargent, Daniel J., Silvia Marsoni, Genevieve Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French et al. „Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer“. Journal of Clinical Oncology 28, Nr. 20 (10.07.2010): 3219–26. http://dx.doi.org/10.1200/jco.2009.27.1825.
Der volle Inhalt der QuelleLiu, Guo-Chen, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan und Pei-Rong Ding. „Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis“. Gastroenterology Research and Practice 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/1798285.
Der volle Inhalt der QuelleFreeman, Karoline, Martin Connock, Ewen Cummins, Tara Gurung, Sian Taylor-Phillips, Rachel Court, Mark Saunders, Aileen Clarke und Paul Sutcliffe. „Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion“. Health Technology Assessment 19, Nr. 91 (November 2015): 1–322. http://dx.doi.org/10.3310/hta19910.
Der volle Inhalt der QuelleZafar, Amna, Zsofia D. Drobni, Matthew Lei, Carlos A. Gongora, Thiago Quinaglia, Uvette Y. Lou, Ramya Mosarla et al. „The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm“. PLOS ONE 17, Nr. 4 (07.04.2022): e0265767. http://dx.doi.org/10.1371/journal.pone.0265767.
Der volle Inhalt der QuelleIkawati, Muthi, und Endah Puji Septisetyani. „Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells“. Indonesian Journal of Cancer Chemoprevention 9, Nr. 1 (28.02.2018): 23. http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss1pp23-31.
Der volle Inhalt der QuelleSholihah, Imroatus, Meirizky Zulharini S., Amalia Miranda, Refki Riswansyah und Riris Istighfari Jenie. „Jure Leaf Extract (Nerium indium Mill.) Increased 5-Fluorouracil Sensitivity through Inhibition of NF-κB Activation and Transporter Protein in WiDr Colon Cancer Cell“. Indonesian Journal of Cancer Chemoprevention 7, Nr. 3 (01.02.2017): 87. http://dx.doi.org/10.14499/indonesianjcanchemoprev7iss3pp87-92.
Der volle Inhalt der QuelleAl-Thani, Hassan, Ayman El-Menyar, Valsa Koshy, Ahmed Hussein, Ahmed Sharaf, Mohammad Asim und Ahmed Sadek. „Implications of Foot Ulceration in Hemodialysis Patients: A 5-Year Observational Study“. Journal of Diabetes Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/945075.
Der volle Inhalt der QuelleMohamed, Yehia I., Aliya Qayyum, Manal Hassan, Lianchun Xiao, Dan G. Duda, Rikita Hatia, Sunyoung S. Lee et al. „Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): e16626-e16626. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16626.
Der volle Inhalt der QuelleHaller, Daniel G., Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger und Hans-Joachim Schmoll. „Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer“. Journal of Clinical Oncology 29, Nr. 11 (10.04.2011): 1465–71. http://dx.doi.org/10.1200/jco.2010.33.6297.
Der volle Inhalt der QuelleBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-Pyo Kim, Baek-Yeol Ryoo und Changhoon Yoo. „Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma.“ Journal of Clinical Oncology 39, Nr. 3_suppl (20.01.2021): 382. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.382.
Der volle Inhalt der QuelleBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-pyo Kim, Baek-Yeol Ryoo und Changhoon Yoo. „Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy“. Therapeutic Advances in Medical Oncology 13 (Januar 2021): 175883592110030. http://dx.doi.org/10.1177/17588359211003053.
Der volle Inhalt der QuelleMcCaffrey, J. A., S. Hilton, M. Mazumdar, S. Sadan, M. Heineman, J. Hirsch, W. K. Kelly, H. I. Scher und D. F. Bajorin. „Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.“ Journal of Clinical Oncology 15, Nr. 6 (Juni 1997): 2449–55. http://dx.doi.org/10.1200/jco.1997.15.6.2449.
Der volle Inhalt der QuelleTesta, Luca, Azeem Latib, Nedy Brambilla, Federico De Marco, Claudia Fiorina, Marianna Adamo, Cristina Giannini et al. „Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis“. European Heart Journal 41, Nr. 20 (06.01.2020): 1876–86. http://dx.doi.org/10.1093/eurheartj/ehz925.
Der volle Inhalt der QuelleHendlisz, Alain, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, Jaarke Vannoote, Katrien De Keukeleire et al. „Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy“. Journal of Clinical Oncology 28, Nr. 23 (10.08.2010): 3687–94. http://dx.doi.org/10.1200/jco.2010.28.5643.
Der volle Inhalt der Quelle